Phaseline

Companies › Incyte Biosciences Japan GK

Incyte Biosciences Japan GK: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
parsaclisib
PI3-kinase p110-delta subunit inhibitor
PIK3CDPhase 1Non Hodgkins LymphomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04661007parsaclisibPhase 1Non Hodgkins LymphomaOncologyDec 2026

Targets

PIK3CD (1)

Companies with the same targets

Pharming Technologies Incyte Kyowa Kirin Rhizen Pharmaceuticals SecuraBio

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.